Achillion Pharmaceuticals Company Profile (NASDAQ:ACHN)

About Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals logoAchillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ACHN
  • CUSIP: 00448Q20
  • Web: www.achillion.com
Capitalization:
  • Market Cap: $566.03 million
  • Outstanding Shares: 136,723,000
Average Prices:
  • 50 Day Moving Avg: $3.73
  • 200 Day Moving Avg: $4.08
  • 52 Week Range: $3.15 - $10.06
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -69.00
  • P/E Growth: -0.390
Sales & Book Value:
  • Annual Revenue: $15 million
  • Price / Sales: 37.74
  • Book Value: $2.80 per share
  • Price / Book: 1.48
Profitability:
  • EBIDTA: ($66,230,000.00)
  • Return on Equity: -9.46%
  • Return on Assets: -9.16%
Debt:
  • Current Ratio: 29.93%
  • Quick Ratio: 29.93%
Misc:
  • Average Volume: 1.41 million shs.
  • Beta: 1.59
  • Short Ratio: 7.2
 

Frequently Asked Questions for Achillion Pharmaceuticals (NASDAQ:ACHN)

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its quarterly earnings results on Thursday, May, 4th. The company reported ($0.15) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.01. During the same period last year, the firm earned ($0.13) EPS. View Achillion Pharmaceuticals' Earnings History.

When will Achillion Pharmaceuticals make its next earnings announcement?

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Achillion Pharmaceuticals.

What guidance has Achillion Pharmaceuticals issued on next quarter's earnings?

Achillion Pharmaceuticals issued an update on its FY17 earnings guidance on Thursday, February, 23rd. The company provided earnings per share (EPS) guidance of -$0.75 to -$0.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.48).

Where is Achillion Pharmaceuticals' stock going? Where will Achillion Pharmaceuticals' stock price be in 2017?

9 brokerages have issued 1 year price targets for Achillion Pharmaceuticals' shares. Their predictions range from $5.00 to $16.00. On average, they expect Achillion Pharmaceuticals' share price to reach $9.75 in the next year. View Analyst Ratings for Achillion Pharmaceuticals.

Are investors shorting Achillion Pharmaceuticals?

Achillion Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totalling 9,253,219 shares, a decrease of 11.9% from the April 28th total of 10,499,931 shares. Based on an average trading volume of 1,087,603 shares, the days-to-cover ratio is currently 8.5 days. Approximately 8.0% of the company's stock are short sold.

Who are some of Achillion Pharmaceuticals' key competitors?

Who owns Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include RA Capital Management LLC (9.97%), Vanguard Group Inc. (0.00%), Janus Capital Management LLC (3.21%), State Street Corp (3.16%), Morgan Stanley (0.00%) and Wellington Management Group LLP (0.00%). Company insiders that own Achillion Pharmaceuticals stock include David Apelian, Jason S Fisherman, Joel C Barrish, Mary Kay Fenton and Nicole Vitullo. View Institutional Ownership Trends for Achillion Pharmaceuticals.

Who sold Achillion Pharmaceuticals stock? Who is selling Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Morgan Stanley, Spark Investment Management LLC, Janus Capital Management LLC, Bellevue Group AG, Renaissance Technologies LLC, Tudor Investment Corp ET AL and UBS Group AG. View Insider Buying and Selling for Achillion Pharmaceuticals.

Who bought Achillion Pharmaceuticals stock? Who is buying Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Eventide Asset Management LLC, HealthInvest Partners AB, Stifel Financial Corp, Teachers Advisors LLC, Dimensional Fund Advisors LP, Credit Suisse AG and Cornerstone Capital Management Holdings LLC.. Company insiders that have bought Achillion Pharmaceuticals stock in the last two years include Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Insider Buying and Selling for Achillion Pharmaceuticals.

How do I buy Achillion Pharmaceuticals stock?

Shares of Achillion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Achillion Pharmaceuticals stock cost?

One share of Achillion Pharmaceuticals stock can currently be purchased for approximately $4.14.

Analyst Ratings

Consensus Ratings for Achillion Pharmaceuticals (NASDAQ:ACHN) (?)
Ratings Breakdown: 2 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $9.75 (135.51% upside)

Analysts' Ratings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017Leerink SwannUpgradeMarket Perform -> Outperform$4.00 -> $6.00HighView Rating Details
4/26/2017Jefferies Group LLCReiterated RatingHoldLowView Rating Details
4/25/2017Maxim GroupLower Price TargetBuy$8.00 -> $5.00HighView Rating Details
4/24/2017Robert W. BairdBoost Price TargetOutperform$5.00 -> $10.00HighView Rating Details
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$10.00N/AView Rating Details
11/4/2016Chardan CapitalUpgradeSell -> Neutral$5.00N/AView Rating Details
11/3/2016WedbushReiterated RatingOutperform$13.00N/AView Rating Details
9/15/2016FBR & CoInitiated CoverageOutperform$16.00N/AView Rating Details
7/7/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$13.00N/AView Rating Details
12/8/2015William BlairReiterated RatingOutperform$16.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Earnings by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
Earnings History by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017        
5/4/2017Q1 2017($0.16)($0.15)ViewN/AView Earnings Details
2/23/2017Q4 2016($0.18)($0.03)$15.00 millionViewN/AView Earnings Details
11/3/2016Q3($0.16)($0.15)ViewN/AView Earnings Details
8/4/2016Q2($0.15)($0.14)ViewN/AView Earnings Details
5/3/2016Q116($0.14)($0.13)ViewN/AView Earnings Details
2/25/2016Q4$0.09$0.12$31.40 million$31.60 millionViewN/AView Earnings Details
11/5/2015Q3$0.09$0.19$32.62 million$33.82 millionViewN/AView Earnings Details
8/10/2015Q2($0.18)($0.25)$0.71 millionViewN/AView Earnings Details
5/7/2015Q115($0.22)($0.17)ViewN/AView Earnings Details
3/5/2015Q414($0.19)($0.21)ViewN/AView Earnings Details
11/4/2014Q314($0.18)($0.16)ViewN/AView Earnings Details
8/7/2014Q214($0.18)($0.16)ViewN/AView Earnings Details
5/7/2014Q114($0.17)($0.17)ViewN/AView Earnings Details
3/7/2014Q413($0.16)($0.14)$0.01 millionViewN/AView Earnings Details
11/12/2013Q3($0.20)($0.14)ViewN/AView Earnings Details
5/7/2013Q113($0.15)($0.14)ViewN/AView Earnings Details
11/8/2012Q312($0.17)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)
2017 EPS Consensus Estimate: ($0.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.17)($0.16)($0.17)
Q2 20173($0.17)($0.17)($0.17)
Q3 20173($0.18)($0.18)($0.18)
Q4 20171($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Achillion Pharmaceuticals (NASDAQ:ACHN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Insider Ownership Percentage: 6.52%
Institutional Ownership Percentage: 77.85%
Insider Trades by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
Insider Trades by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/22/2016Jason S FishermanDirectorBuy10,000$3.96$39,600.00View SEC Filing  
12/5/2016Mary Kay FentonCFOBuy2,500$4.11$10,275.00View SEC Filing  
12/2/2016Joel C BarrishInsiderBuy2,500$4.06$10,150.00View SEC Filing  
12/30/2015David ApelianinsiderSell10,000$10.50$105,000.00View SEC Filing  
12/28/2015Mary Kay FentonCFOSell43,500$10.08$438,480.00View SEC Filing  
11/11/2015Nicole VitulloDirectorSell550,000$10.17$5,593,500.00View SEC Filing  
9/25/2015Nicole VitulloDirectorSell9,310$8.22$76,528.20View SEC Filing  
1/23/2015Mary Kay FentonCFOSell13,125$16.00$210,000.00View SEC Filing  
1/21/2015Milind DeshpandeCEOSell100,000$15.00$1,500,000.00View SEC Filing  
9/30/2014Ra Capital Management, LlcInsiderSell1,332,014$10.20$13,586,542.80View SEC Filing  
9/29/2014Ra Capital Management, LlcInsiderSell221,014$10.96$2,422,313.44View SEC Filing  
9/26/2014Ra Capital Management, LlcMajor ShareholderSell2,372,915$11.17$26,505,460.55View SEC Filing  
9/25/2014Ra Capital Management, LlcMajor ShareholderSell497,986$11.05$5,502,745.30View SEC Filing  
9/24/2014Ra Capital Management, LlcMajor ShareholderSell1,204,929$11.27$13,579,549.83View SEC Filing  
9/23/2014Ra Capital Management, LlcMajor ShareholderSell2,595,071$11.29$29,298,351.59View SEC Filing  
9/2/2014Ra Capital Management, LlcMajor ShareholderSell835,293$11.63$9,714,457.59View SEC Filing  
8/27/2014Ra Capital Management, LlcMajor ShareholderSell2,711,352$11.33$30,719,618.16View SEC Filing  
8/26/2014Ra Capital Management, LlcMajor ShareholderSell2,112,867$11.35$23,981,040.45View SEC Filing  
8/25/2014Joseph TruittEVPSell25,000$10.82$270,500.00View SEC Filing  
8/25/2014Ra Capital Management, LlcMajor ShareholderSell331,396$10.96$3,632,100.16View SEC Filing  
8/18/2014Milind DeshpandeCEOSell216,624$10.00$2,166,240.00View SEC Filing  
8/18/2014Ra Capital Management, LlcMajor ShareholderSell4,235,000$9.53$40,359,550.00View SEC Filing  
8/15/2014Michael D KishbauchDirectorSell495,812$9.40$4,660,632.80View SEC Filing  
8/13/2014Gary E FrashierDirectorSell5,000$8.00$40,000.00View SEC Filing  
6/20/2014Ra Capital Management, LlcInsiderSell880,000$8.40$7,392,000.00View SEC Filing  
6/16/2014Gary E FrashierDirectorSell55,000$8.00$440,000.00View SEC Filing  
6/16/2014Joseph TruittEVPSell25,000$7.82$195,500.00View SEC Filing  
6/16/2014Qvt Associates Gp LlcMajor ShareholderSell1,819,551$7.70$14,010,542.70View SEC Filing  
6/11/2014Qvt Associates Gp LlcMajor ShareholderSell128,649$7.66$985,451.34View SEC Filing  
6/10/2014Joseph TruittEVPSell50,000$6.02$301,000.00View SEC Filing  
6/10/2014Michael D KishbauchDirectorSell371,937$7.75$2,882,511.75View SEC Filing  
12/30/2013Qvt Associates Gp Llcmajor shareholderSell170,239$3.34$568,598.26View SEC Filing  
12/26/2013Qvt Associates Gp Llcmajor shareholderSell121,205$3.44$416,945.20View SEC Filing  
12/23/2013Qvt Associates Gp Llcmajor shareholderSell289,141$3.24$936,816.84View SEC Filing  
12/19/2013Qvt Associates Gp Llcmajor shareholderSell222,612$3.09$687,871.08View SEC Filing  
12/17/2013Qvt Associates Gp Llcmajor shareholderSell92,803$3.11$288,617.33View SEC Filing  
11/22/2013Dennis LiottaDirectorBuy10,000$2.98$29,800.00View SEC Filing  
11/20/2013Ra Capital Management, LlcInsiderBuy1,110,000$2.55$2,830,500.00View SEC Filing  
11/19/2013Jason FishermanDirectorBuy15,000$2.63$39,450.00View SEC Filing  
11/12/2013Ra Capital Management, LlcInsiderBuy1,795,000$2.48$4,451,600.00View SEC Filing  
10/31/2013Ra Capital Management, LlcInsiderBuy1,186,007$2.45$2,905,717.15View SEC Filing  
10/14/2013Ra Capital Management, LlcInsiderBuy2,369,229$2.79$6,610,148.91View SEC Filing  
10/11/2013Ra Capital Management, LlcInsiderBuy2,448,710$2.56$6,268,697.60View SEC Filing  
9/30/2013Ra Capital Management, LlcInsiderBuy2,800,000$2.98$8,344,000.00View SEC Filing  
8/14/2013Jason FishermanDirectorBuy5,000$6.83$34,150.00View SEC Filing  
8/12/2013Dennis LiottaDirectorBuy5,000$6.47$32,350.00View SEC Filing  
8/9/2013Qvt Associates Gp Llcmajor shareholderBuy102,282$6.41$655,627.62View SEC Filing  
7/11/2013Qvt Associates Gp LlcMajor ShareholderBuy401,017$6.46$2,590,569.82View SEC Filing  
7/10/2013Qvt Associates Gp LlcMajor ShareholderBuy390,944$6.33$2,474,675.52View SEC Filing  
7/8/2013Qvt Associates Gp LlcMajor ShareholderBuy642,509$6.28$4,034,956.52View SEC Filing  
7/3/2013Qvt Associates Gp LlcMajor ShareholderBuy1,963,248$6.43$12,623,684.64View SEC Filing  
7/1/2013Gary E FrashierDirectorSell5,000$8.17$40,850.00View SEC Filing  
6/21/2013Jason S FishermanDirectorBuy10,000$7.63$76,300.00View SEC Filing  
6/7/2013Gary E FrashierDirectorSell5,000$8.37$41,850.00View SEC Filing  
6/3/2013Jason S FishermanDirectorBuy10,000$7.87$78,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Achillion Pharmaceuticals (NASDAQ:ACHN)
Latest Headlines for Achillion Pharmaceuticals (NASDAQ:ACHN)
Source:
DateHeadline
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. Forecasted to Earn FY2018 Earnings of ($0.28) Per Share (ACHN)
www.americanbankingnews.com - May 22 at 9:34 AM
finance.yahoo.com logoWhy Achillion Pharmaceuticals Stock Is Jumping 15% Today
finance.yahoo.com - May 18 at 3:16 PM
finance.yahoo.com logoAchillion: It Can't Get Any Worse…Or Can It?
finance.yahoo.com - May 18 at 12:34 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Upgraded to "Outperform" by Leerink Swann
www.americanbankingnews.com - May 18 at 8:10 AM
finance.yahoo.com logoAchillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : May 11, 2017
finance.yahoo.com - May 11 at 8:28 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 10 at 1:34 PM
finance.yahoo.com logoAchillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : May 10, 2017
finance.yahoo.com - May 10 at 9:37 AM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Expected to Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - May 9 at 7:44 AM
finance.yahoo.com logoAchillion (ACHN) Reports Wider-than-Expected Loss in Q1
finance.yahoo.com - May 8 at 3:16 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. Expected to Earn FY2019 Earnings of $0.38 Per Share (ACHN)
www.americanbankingnews.com - May 8 at 12:12 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 3:58 PM
finance.yahoo.com logoAchillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs
finance.yahoo.com - May 4 at 3:17 PM
marketbeat.com logoAchillion reports 1Q loss
marketbeat.com - May 4 at 6:27 AM
finance.yahoo.com logoAchillion to Present at the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - May 2 at 3:21 PM
americanbankingnews.com logoAchillion Pharmaceuticals (ACHN) Earning Favorable Media Coverage, Study Shows
www.americanbankingnews.com - May 2 at 7:52 AM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 1 at 12:02 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 1:30 AM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 1:21 AM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 29 at 1:20 AM
americanbankingnews.com logoAchillion Pharmaceuticals (ACHN) Earning Favorable News Coverage, Analysis Finds
www.americanbankingnews.com - April 27 at 2:04 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - April 26 at 6:22 PM
finance.yahoo.com logoETFs with exposure to Achillion Pharmaceuticals, Inc. : April 25, 2017
finance.yahoo.com - April 26 at 5:42 AM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Rating Reiterated by Maxim Group
www.americanbankingnews.com - April 25 at 11:23 AM
fool.com logoWhy Achillion Pharmaceuticals Stock Sank on Monday
www.fool.com - April 25 at 9:27 AM
americanbankingnews.com logoAchillion Pharmaceuticals' (ACHN) Outperform Rating Reiterated at Robert W. Baird
www.americanbankingnews.com - April 24 at 4:42 PM
streetinsider.com logoAchillion Pharma (ACHN) Reports Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6 ... - StreetInsider.com
www.streetinsider.com - April 24 at 3:20 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Very Likely to Affect Achillion Pharmaceuticals (ACHN) Share Price
www.americanbankingnews.com - April 24 at 11:47 AM
streetinsider.com logoAchillion Pharma (ACHN) Reports Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178
www.streetinsider.com - April 24 at 11:16 AM
finance.yahoo.com logoAchillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178
finance.yahoo.com - April 22 at 10:55 AM
americanbankingnews.com logoFavorable News Coverage Very Likely to Affect Achillion Pharmaceuticals (ACHN) Share Price
www.americanbankingnews.com - April 21 at 8:17 AM
americanbankingnews.com logoZacks: Analysts Anticipate Achillion Pharmaceuticals, Inc. (ACHN) to Post -$0.10 EPS
www.americanbankingnews.com - April 18 at 11:38 AM
americanbankingnews.com logoAchillion Pharmaceuticals (ACHN) Getting Positive News Coverage, Analysis Finds
www.americanbankingnews.com - April 17 at 10:07 AM
americanbankingnews.com logoSomewhat Positive Press Coverage Very Likely to Impact Achillion Pharmaceuticals (ACHN) Stock Price
www.americanbankingnews.com - April 13 at 1:28 PM
streetinsider.com logoAchillion Pharma (ACHN) to Initiate Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria
www.streetinsider.com - April 7 at 5:35 AM
finance.yahoo.com logoAchillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria
finance.yahoo.com - April 7 at 5:35 AM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Sees Large Increase in Short Interest
www.americanbankingnews.com - April 4 at 3:21 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Corbus Pharmaceuticals
finance.yahoo.com - March 31 at 3:23 PM
bizjournals.com logoBiotech Stocks Under Scanner -- Celsion, Achillion Pharma, Tenax Therapeutics, and Cerulean Pharma
www.bizjournals.com - March 29 at 8:52 AM
finance.yahoo.com logoWhy Is Achillion (ACHN) Down 11.3% Since the Last Earnings Report? - Yahoo Finance
finance.yahoo.com - March 28 at 3:17 PM
americanbankingnews.com logoTheStreet Downgrades Achillion Pharmaceuticals, Inc. (ACHN) to D
www.americanbankingnews.com - March 26 at 11:43 PM
streetinsider.com logoAchillion Pharma (ACHN) Granted USPTO Matter Patent for Small Molecule Complement Alternative Pathway Factor D Inhibitors
www.streetinsider.com - March 22 at 1:37 AM
streetinsider.com logoAfter-Hours Stock Movers 03/21: (DLTH) (SLW) (FDX) Higher; (RGNX) (ADAP) (NKE) Lower (more...)
www.streetinsider.com - March 21 at 8:35 PM
us.rd.yahoo.com logoUSPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors
us.rd.yahoo.com - March 21 at 8:35 PM
seekingalpha.com logoAchillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference 2017
seekingalpha.com - March 17 at 8:29 PM
thestreet.com logoThese 5 Stocks Under $10 Could Explode Up Soon
www.thestreet.com - March 2 at 3:19 PM
finance.yahoo.com logoAerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?
finance.yahoo.com - March 1 at 8:18 PM
finance.yahoo.com logoACHILLION PHARMACEUTICALS INC Financials
finance.yahoo.com - March 1 at 3:16 PM
nasdaq.com logoAchillion Pharmaceuticals to Support a Natural History Study of C3 ...
www.nasdaq.com - February 28 at 3:19 PM
streetinsider.com logoAchillion Pharma (ACHN) to Support Natural History Study of C3 Glomerulopathy - StreetInsider.com
www.streetinsider.com - February 28 at 7:19 AM
finance.yahoo.com logoAchillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London
finance.yahoo.com - February 28 at 7:19 AM

Social

Chart

Achillion Pharmaceuticals (ACHN) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff